Modelling the cost-effectiveness of cervical cancer screening with HPV self-sampling and molecular triage for women aged 60-69 years
2025 (English)In: Discover Oncology, E-ISSN 2730-6011, Vol. 16, no 1, article id 805Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Since 2022, self-sampling has been recommended in Sweden's cervical screening program. Despite still being used primarily for long-term non-attendees, its expected increase in use raises interest in molecular triage methods applicable to self-collected samples. Postmenopausal women face screening challenges due to physiological changes, making this group particularly relevant for evaluating alternative strategies. This study models the cost-effectiveness of different sampling and triage methods in identifying histological high-grade squamous intraepithelial lesions (HSIL) in women aged 60-69 years.
METHODS: Using real-world data, this study compares the cost-effectiveness of currently implemented strategy based on professional HPV sampling and combination triage with genotyping and cytology, with modelled strategies based on self-sampling and various molecular triage. The comparison evaluates healthcare resource use and the number of identified histological HSIL cases. The analysis focuses on a single screening cycle, re-testing of invalid samples or screening-positive/triage-negative women are not addressed.
RESULTS: Screening with molecular triage either leads to decreases in effect, i.e. fewer histological HSIL identified, or significant cost increases due to higher rate of HPV-positive screening samples and higher number of colposcopy follow-ups.
CONCLUSIONS: Molecular triage, whether used with self-sampling or professional sampling, does not appear cost-effective for identifying HSIL in this age group compared to the current screening strategy.
Place, publisher, year, edition, pages
Springer, 2025. Vol. 16, no 1, article id 805
Keywords [en]
Cervical screening, Cost-effectiveness, Economic evaluation, Genotyping, HPV, HSIL, Methylation, Self-sampling
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-121115DOI: 10.1007/s12672-025-02432-3ISI: 001490233600007PubMedID: 40383738Scopus ID: 2-s2.0-105005432867OAI: oai:DiVA.org:oru-121115DiVA, id: diva2:1959103
Funder
Örebro UniversityRegion Örebro County, OLL-989120
Note
Open access funding provided by Örebro University. This work was supported by the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement [grant number OLL-985774] and by the Gynecological Oncology Foundation at Region Örebro County [grant number OLL-989120].
2025-05-192025-05-192025-07-08Bibliographically approved